



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_191_25

You asked:

I have a freedom of information request regarding the treatment of Multiple Myeloma. Could you please answer the following questions.

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

- 104 patients.
- Other centres that CTMUHB utilise: Singleton at Swansea Bay University Health Board and Velindre Cancer Centre.

Q2. Of the multiple myeloma patients treated over the past 6 months, how many were treated with the following:

- Any other systemic anti-cancer therapy - ** (Cyclophosphamide with Dexamethasone)
- Belantamab Mafodotin [Blenrep] - 0
- Belantamab Mafodotin [Blenrep] with bortezomib and dexamethasone - 0
- Belantamab Mafodotin [Blenrep] with pomalidomide and dexamethasone 0
- Bortezomib [Velcade] monotherapy or with dexamethasone - **
- Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) - 0
- Bortezomib, thalidomide and dexamethasone [VTD] - 0
- Carfilzomib [Kyprolis] and dexamethasone 0
- Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone - 0
- Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone - 13
- Daratumumab [Darzalex] monotherapy - **
- Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVD or DBd) - 24
- Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTD) - 12
- Elranatamab - **
- Idecabtagene vicleucel [Abecma] - 0
- Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) - **
- Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd) - 15
- Lenalidomide [Revlimid] and dexamethasone - 11
- Lenalidomide [Revlimid] monotherapy - 15
- Panobinostat in combination with Bortezomib and Dexamethasone - 0
- Pomalidomide [Imnovid] and dexamethasone - 5
- Selinexor and dexamethasone - **

- Selinexor, Bortezomib [Velcade] and dexamethasone - 0
- Talquetamab - 0
- Teclistamab [Tecvayli] - 0

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.